(PYPD) PolyPid Ltd. Marketing Mix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(PYPD) PolyPid Ltd. Complete Analysis Pack
Visual. Strategic. Downloadable.
This PolyPid Ltd. 4P's Marketing Mix Analysis summarizes Product, Price, Place and Promotion to show how the company positions and sells its offerings; the page includes a real preview/sample so you can judge style and depth. Purchase the full version to download the complete, ready-to-use analysis for presentations, strategy or research.
Product
D-PLEX100 lead candidate
PolyPid Ltd. centers its product mix on D-PLEX100, its lead advanced-stage candidate and flagship asset as of July 2026. The surgical-use program targets local, sustained antibiotic release to help prevent surgical site infections, a market with millions of procedures each year. In PolyPid Ltd., D-PLEX100 remains the main source of pipeline value and investor focus.
PLEX platform
PLEX is PolyPid Ltd.'s proprietary polymer-lipid encapsulation matrix and the core of D-PLEX100. It is designed to release anti-infective treatment locally at the surgical site, not through standard systemic delivery. In PolyPid’s latest annual filing, the company still had no commercial sales, so PLEX remains its main technology and value driver.
Phase III status
D-PLEX100 is in Phase III clinical development, the last big step before possible regulatory filing if results stay positive. This stage tests safety and efficacy in larger patient groups, and late-stage data can move valuation fast because success can unlock approval odds while failure can erase most of the program’s value.
SSI prevention
PolyPid Ltd.'s SSI prevention asset targets surgical site infections, a high-cost hospital-acquired complication that affects about 2% to 5% of surgeries and can add $11,000 to $25,000 per case in treatment costs. This is the clearest clinical use case for the product because fewer SSIs mean better outcomes, shorter stays, and lower readmission risk.
It also fits a real unmet need: even with standard prevention, SSIs remain one of the most common post-op infections worldwide.
- Targets a major hospital-acquired infection
- Best-fit use case for PolyPid Ltd.
- Can cut avoidable treatment costs
- Supports better post-surgery outcomes
Sternal and abdominal procedures
PolyPid is studying D-PLEX100 in sternal and abdominal surgeries, covering both bone and soft-tissue procedures. Surgical site infections affect about 2% to 5% of patients after surgery, so both settings carry real clinical need. That dual use widens the product’s market reach.
- Two high-risk surgery types
- Broader commercial use case
- Targets infection-heavy procedures
PolyPid’s Phase III SSI Play: D-PLEX100 Carries the Story
PolyPid Ltd.'s Product focus is D-PLEX100, a Phase III, local antibiotic-delivery implant built on the PLEX matrix as of July 2026. It targets surgical site infections, which occur in about 2% to 5% of surgeries and can add $11,000 to $25,000 per case. With no commercial sales, Product value still rests on late-stage data and approval odds.
| Metric | Value |
|---|---|
| Lead Product | D-PLEX100 |
| Stage | Phase III |
| Use | SSI prevention |
| SSI rate | 2% to 5% |
What is included in the product
Detailed Word Document
Provides a concise, company-specific 4P’s analysis of PolyPid Ltd.’s marketing strategy, with practical insights into product, pricing, placement, and promotion.
Editable Excel File
Summarizes PolyPid’s 4Ps as a quick, decision-ready snapshot for fast alignment and easier marketing planning.
Reference Sources
Provides a concise, traceable bibliography of industry reports, clinical data, and regulatory sources to speed due diligence and validate PolyPid Ltd.’s key assumptions.
Place
Petah Tikva, Israel HQ
PolyPid Ltd. is headquartered in Petah Tikva, Israel, and the site anchors its corporate, scientific, and administrative work. Israel is the company’s main development base, supporting coordination across its global trial and regulatory programs, including the Phase 3 SHIELD I study with 1,200 patients. That makes the HQ a key hub for product, people, and pipeline control.
Clinical trial sites
PolyPid Ltd. reaches patients first through hospital clinical trial sites, not retail channels. In Phase III, investigator sites are the gatekeepers for surgeon and patient access, and they generate the safety and efficacy data needed for future market entry. For a late-stage study, every enrolled patient and protocol visit adds directly to the evidence package regulators review.
Hospital channel
If approved, D-PLEX100 would sit inside hospital surgical workflows, with use in the operating room and early post-op care. That makes the channel institutional and B2B, sold through hospital buyers, not patients. In PolyPid Ltd.'s Phase 3 program, the target use case is high-volume surgery, where even a small infection-rate drop can matter.
Regulatory market access
PolyPid Ltd.’s place strategy is approval-led: commercial access starts only after each market’s regulator clears the product, so rollout is likely country by country. That is standard for late-stage biopharma and keeps launch timing tied to local review speed, not one global date. In 2025, this meant no broad, simultaneous market access.
- Country-by-country launch
- Approval timing drives access
- Standard biopharma distribution path
Healthcare partnerships
Biopharma commercialization often runs through healthcare distributors or strategic licensees, and that path fits PolyPid Ltd.’s hospital-led model. If business development lands the right partners, PolyPid’s reach can extend into surgical hospitals across more regions, while the exact footprint will hinge on deal terms and execution. One signed regional license can change access faster than direct sales alone.
- Partner-led launch can speed hospital access
- Licensees can widen regional coverage
- Final reach depends on BD outcomes
PolyPid’s Hospital-First Launch Hinges on Trial Site Access
PolyPid Ltd.’s place is hospital-led and approval-led: D-PLEX100 reaches users through clinical trial sites first, then country-by-country hospital launch after regulator clearance. In Phase 3 SHIELD I, 1,200 patients were enrolled, so site access is central to evidence generation and future rollout.
| Place metric | Data |
|---|---|
| HQ | Petah Tikva, Israel |
| Phase 3 | 1,200 patients |
| Launch path | Country by country |
Preview Before You Purchase
PolyPid Ltd. Reference Sources
The preview shown here is the exact PolyPid Ltd. 4P's Marketing Mix analysis you’ll receive instantly after purchase—fully complete and ready to use, no surprises.
Promotion
Scientific data releases
In PolyPid Ltd.'s Phase III push, scientific data releases are the core promotion tool because doctors and partners buy into trial results, not ads. The company's lead asset D-PLEX100 was tested in a 1,498-patient Phase III program, so safety, efficacy, and study-design updates drive trust. This evidence-led approach matters because one strong readout can shift licensing talks and financing.
Medical congress presence
PolyPid Ltd. can use medical congresses to present data to surgeons, infection specialists, and hospital buyers, the same audience that shapes adoption in late-stage biopharma. One major meeting can draw thousands of clinicians and dozens of peer-reviewed abstracts, so a single presentation can lift visibility fast. This channel also builds peer credibility, which matters when a hospital committee is weighing a new technology.
Investor relations
PolyPid’s investor relations is a key promotion channel because, as a clinical-stage public company, its value moves on pipeline milestones, not sales. In 2025, earnings materials, corporate updates, and SEC filings were used to explain trial progress and funding needs. That matters because one readout can shift the stock fast.
Peer-reviewed publications
Peer-reviewed publications help PolyPid Ltd. turn preclinical and clinical data into trusted evidence, which matters for a hospital-use product. Articles in indexed journals reach clinicians and procurement teams beyond conference halls, and that broader visibility can support adoption when institutions want published proof, not just slide decks.
- Builds clinical trust
- Extends trial reach
- Supports hospital buying decisions
- Validates the platform
Partnering outreach
PolyPid Ltd. uses partnering outreach as promotion by holding business development talks with pharma peers. For a late-stage asset, licensing or co-commercialization can open market access and bring funding support, which matters as much as ads in biopharma.
Those talks aim to turn clinical value into deal terms, shared sales reach, and lower launch risk. For PolyPid Ltd., the partner pitch is a core promotional tool, not a side task.
- Targets licensing or co-commercialization
- Seeks market access support
- Seeks funding support
PolyPid Sells D-PLEX100 With Clinical Proof, Not Ads
PolyPid Ltd. promotes D-PLEX100 through data-first channels: Phase III results, congress talks, peer-reviewed papers, investor updates, and partner outreach. Its 1,498-patient Phase III program and 2025 SEC filings make trial proof the main sales tool, since hospital buyers and licensing peers respond to clinical evidence, not broad consumer ads.
| Channel | Role | Key fact |
|---|---|---|
| Data releases | Build trust | 1,498 patients |
| Conferences | Reach clinicians | Peer visibility |
| IR | Guide investors | 2025 filings |
Price
No commercial list price
As of July 2026, PolyPid Ltd. has no public commercial list price for D-PLEX100, because it is still in late-stage development and not yet a routine marketed therapy. The price is not set in a normal retail sense, and the key near-term work is clinical and regulatory progress, not sales rollout. In Phase 3, the program is still focused on proving value before any commercial pricing can be fixed.
Pre-approval valuation
For PolyPid Ltd., price is mainly a pre-approval valuation, not an end-user bill, because the asset is still development-stage. Investors price it through equity markets based on trial progress, approval odds, and market size, so each clinical update can re-rate the stock fast. That differs from standard product pricing, where revenue starts only after launch.
Value-based hospital economics
If commercialized, PolyPid Ltd. would likely price on SSI prevention value, not just product cost. Hospital studies show a surgical site infection can add about 7 to 11 days of stay and roughly $11,000 to $29,000 in extra cost per case, so the case for adoption rests on avoided infections, shorter stays, and lower readmissions.
Reimbursement dependent
PolyPid Ltd.'s pricing for hospital-use products is likely to hinge on payer coverage, not list price alone. In the U.S., Medicare's New Technology Add-on Payment can cover up to 75% of eligible incremental cost for up to 2 years, which shows why reimbursement can make or break uptake. Without payer alignment, even strong clinical products can see slow adoption.
- Price follows reimbursement logic.
- Coverage drives hospital adoption.
- Without payers, uptake stays limited.
Specialty premium range
D-PLEX100, if approved, should sit in a specialty premium range, not commodity hospital pricing. Its final price will hinge on label status, dose count, and the size of SSI reduction; products that cut costly surgical site infections can justify higher net prices. PolyPid’s pricing power will depend on proving a clear, repeatable reduction in complications versus standard care.
- Premium pricing needs proven SSI reduction.
- Approval and dosing drive net price.
- Complication savings support higher reimbursement.
D-PLEX100: No Price Yet, But SSI Savings Could Drive Value
As of July 2026, PolyPid Ltd. has no public commercial price for D-PLEX100, because it is still pre-launch and pricing will depend on approval and reimbursement. In hospital use, price will likely be set by avoided SSI costs, which can add 7 to 11 days of stay and $11,000 to $29,000 per case. Medicare NTAP can cover up to 75% of eligible incremental cost for 2 years, so payer support is key.
| Price factor | Current read |
|---|---|
| Public list price | None yet |
| SSI extra cost | $11,000-$29,000 |
| Extra stay | 7-11 days |
| NTAP support | Up to 75% |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.